

August 2020

# Using Data Collection for Quality Improvement

Michigan Primary Care Association

[www.mpca.net](http://www.mpca.net)

# Session Objectives:

- Identify the data available in Azara
- Understand ways to utilize the data in Azara for quality improvement
- Integrating SUD data for whole person care
- Use data to identify patients at high risk

# Status in the State of Michigan

- 26 out of 30 Health Centers on Azara have implemented the Controlled Substance Module
- Custom Registries, Custom Reports, Scorecards and Dashboards

A purple-tinted background image showing a woman and a young child looking at a tablet together. The woman is on the right, holding the tablet, and the child is on the left, looking at the screen. The text "Viewing the Data in Azara" is overlaid in the center in white.

# Viewing the Data in Azara

# Controlled Substance Management Module



Early identification of patients at risk for alcohol and substance misuse



Tracking and Management of High Risk Populations



Monitoring High Risk Medication Use



Assess the impact of education and changes to workflow on number of patients with active opioids or in treatment



# Measures – Substance Disorder and Rx (6)

## Alcohol Use Disorder Treatment (AUD)

Patients with an active medication for alcohol use disorder (AUD) during the reporting period.

## Opioid Use Disorder Treatment (OUD)

Patients with an active medication for opioid use disorder (OUD) during the reporting period.

## Buprenorphine Prescription

Patients with at least one active Buprenorphine medication during the reporting period.

## Naltrexone-Injectable Prescription

Patients with at least one active Naltrexone-Injectable medication provided during the reporting period.

## Controlled Substance Agreement (CNMP)

Patients with CNMP or COT who have signed a controlled substance agreement in the last 12 months.

## Controlled Substance Agreement (COT)

Patients with COT who have signed a controlled substance agreement in the last 12 months.

CNMP-Chronic Non-Malignant Pain  
COT-Chronic Opioid Therapy

# Measures – Medication Management (6)

## Opioid on Med List

Patients with an active opioid medication on medication list during the reporting period.

## Benzodiazepine Usage

Patients with an active benzodiazepine during the reporting period.

## Opioid and Benzodiazepine

Patients with both an active Opioid and an active Benzodiazepine at the same time during the reporting period.

## Benzodiazepine Dose >3mg

Patients on a benzodiazepine dose > 3mg

## Naloxone Prescription with COT

Patients on a Chronic Opioid Therapy (COT) medication for more than 90 days with a Naloxone prescription in the last 12 months

## Naloxone Prescription with CNMP

Patients with a diagnosis of Opioid Use Disorder with a naloxone prescription in the last 12 months.

Early  
2020

CNMP-Chronic Non-Malignant Pain  
COT-Chronic Opioid Therapy

# Initiation/Engagement/Retention in Treatment (5)

## Initiation of AOD Treatment 13+ Years Old\* (NQF 0004)

Patients with a new episode of alcohol and other drug (AOD) dependence who initiated treatment within 14 days of the diagnosis.

## Engagement of AOD Treatment 13+ Years Old\* (NQF 0004)

Patients with a new episode of alcohol and other drug (AOD) dependence who initiated treatment and who had two or more additional services with an AOD diagnosis within 30 days of the initiation visit.

## Initiation of Pharmacotherapy Upon New Episode of Opioid Dependence (13-17 and 18+ Years)

Patients who initiate pharmacotherapy with at least 1 prescription for opioid treatment medication within 30 days following a diagnosis of opioid dependence (OUD).

## Continuity of Pharmacotherapy for Opioid Use Disorder (NQF 3175)

Adults aged 18 years and older with pharmacotherapy for opioid use disorder (OUD) who have at least 180 days of continuous treatment

Early  
2020

\* Filters can be used to see results for different age ranges.



# Prevention/Screening (7)

## Unhealthy Alcohol Use: Screening & Brief Counseling (NQF 2152)

Patients aged 18 years and older who were screened for unhealthy alcohol use, at least once within the last 24 months AND received brief counseling if identified as an unhealthy alcohol user.

## Unhealthy Alcohol Use: Screening (NQF 2152 Modified)

Patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once in the last 24 months.

## Drug Use Screening (NQF 2597 Modified)

Patients aged 18 years and older who were screened for non-medical prescription drug use and illicit drug use using a systematic screening method at least once within the last 24 months.

And  
Counseling

## Hepatitis C Lifetime Screening

Patients aged 12+ who had at least one Hepatitis C screening in their lifetime.

## Hepatitis C Screening After Opioid Use Disorder Diagnosis

Patients aged 12+ who had at least one Hepatitis C screening on or after an Opioid Use Disorder (OUD) Dx.

## Substance Use Screening and Intervention Composite (NQF 2597 modified)

Patients aged 18 years and older were screened at least once within the last 24 months for unhealthy alcohol use, nonmedical prescription drug use, and illicit drug use AND who received an intervention for all positive screening results.

Late  
2019

# Reports

Controlled Substance FILTER ^

REPORT ⋮

PERIOD: August 2020 | CENTERS: All Centers | RENDERING PROVIDER: All Rendering Provid... | USUAL PROVIDER: All Usual Provider

+ Add Filter | | Update

REPORT


+ CARE GAPS

GROUPING: No Grouping

REPORT FORMAT: Scorecard


MEASURE	RESULT	NUMERATOR	DENOMINATOR	EXCLUSIONS	
Opioid Use Disorder Treatment (OUD)	80.6%	2,199	2,729	0	
Alcohol Use Disorder Treatment (AUD)	17.2%	365	2,116	0	
Initiation of AOD Treatment 13+ Years Old (NQF 0004)	48.0%	501	1,043	1,175	
Engagement of AOD Treatment 13+ Years Old (NQF 0004)	28.2%	294	1,043	1,175	
Continuity of Pharmacotherapy for Opioid Use Disorder (NQF 3175)	71.4%	322	451	324	
Initiation of Pharmacotherapy Upon New Episode of Opioid Dependence (13-17 Years)	0.0%	0	1	0	
Initiation of Pharmacotherapy Upon New Episode of Opioid Dependence (18+ Years)	50.1%	510	1,017	0	
Buprenorphine Prescription	40.5%	1,106	2,729	0	


PERIOD: August 2020  
CENTERS: All Centers  
RENDERING PROVIDER: All Rendering Provid...

+ Add Filter  Update


MEASURE ANALYZER

 **DETAIL LIST**

 VALUE SETS

Search Patients ... 

All Gaps Num Excl

 Measure Investigation Tool

DEMOGRAPHI... >			OPIOID RX							
CENTER NAME	NAME	MRN	OP DATE	DETAIL	DATE	QUANTITY	REFILLS	NAME	PRESCRIBER ↓	CODE
			14/2020	Hydrocodo...	8/14/2020	30	0	APAP 325 ...		856999
				Norco	8/12/2020	75	0	NORCO 7.5...		857007
				Norco	8/25/2020	90	0	NORCO 7.5...		857007
				Tramadol ...	7/23/2020	28	0	traMADol ...		835603
				Tylenol wit...	8/14/2020	15	0	MS 30 MG ...		892672
				Tylenol wit...	8/11/2020	120	2	Tylenol #3 ...		993837
			10/2020	Hydrocodo...	3/16/2020	24	0	APAP 325 ...		857002

# Registries

- Drug Use Screen
- Opioid Medication – Potential Misuse
- Methadone Medication
- Pain Management
- MPCA SUD Innovations Grant Quarterly Report



DATE RANGE: 08/20/2020-08/27/2020   
 CENTERS: All Centers   
 RENDERING PROVIDER: All Rendering Provid...

+ Add Filter Update

REGISTRY

VALUE SETS

Search Patients ...




CENTER NAME	DRUGS OF ABUSE			ALCOHOL DISORDER DX	
	DATE	TEST AND RESULT	POS TEST	DATE	CODE
	3/5/2018	Phencyclidine - NEGATIVE	Opiates - 03/05/2018		
	3/12/2017	Amphetamines - NEGATIVE	Opiates - 03/12/2017		
	2/25/2018	Opiates - POSITIVE	Opiates - 02/25/2018		
	1/7/2018	Opiates - CONSISTENT	Opiates - 01/07/2018, Ethanol - 08/18/2017, Amphetamines - 08/18/2017	11/2/2017	F10.10
	2/6/2018	Opiates - CONSISTENT	Opiates - 02/06/2018, Ethanol - 10/11/2016	3/25/2014	F10.20

# Alerts

Name	PVP Name	Description
Alcohol Screen	Alcohol Screening	Alert will trigger for patients ages >= 14 who have not had an alcohol screen in the last year. This alert is not configurable
Controlled Substance Agreement	Ctrl Sub	Alert will trigger if Control Substance Agreement has not occurred in the last 1 years. Patient must have Long term (current) use of opiate analgesic (Z79.891) or Chronic Non-malignant Pain. Patient must have Palliative Care or hospice care or Hospice Care.
Drug Screen	Drug Screening	Alert will trigger for patients ages >= 14 who have not had a drug screen assessment in the last year. This alert is not configurable
Substance Use Screening	Sub Use Scr	Alert will trigger if a patient 18+ has not had Substance Use Screening (drug and alcohol) documented within the last 12 months. This alert is not configurable

NAME	PVP NAME	ENABLED	DESCRIPTION
Alcohol Screen	Alcohol Screening	Y	Alert will trigger for patients ages >= 14 who have not had an alcohol screen in the last year. This alert is not configurable
Alcohol Screen	Alcohol Screening	Y	Alert will trigger for patients ages >= 14 who have not had an alcohol screen in the last year. This alert is not configurable
Alcohol Screen	Alcohol Screening	Y	Alert will trigger for patients ages >= 14 who have not had an alcohol screen in the last year. This alert is not configurable
Alcohol Screen	Alcohol Screening	Y	Alert will trigger for patients ages >= 14 who have not had an alcohol screen in the last year. This alert is not configurable
Alcohol Screening	AUDIT-C	Y	Alert will trigger if AUDIT Screening has not occurred in the last 1 years. Alert only applies to patients >= 12 yrs old.
Alcohol Screening	AUDIT	Y	Alert will trigger if AUDIT Screening has not occurred in the last 1 years. Alert only applies to patients >= 18 mths old.
Alcohol Screening	AUDIT	Y	Alert will trigger if AUDIT Screening has not occurred in the last 1 years. Alert only applies to patients >= 18 yrs old and <= 150 yrs old.
Alcohol Screening	Alcohol Screening - 18+	Y	Alert will trigger if AUDIT Screening has not occurred in the last 1 years. Alert only applies to patients >= 18 yrs old.


# Alerts

	<b>Sex at Birth:</b> M <b>GI:</b> <b>SO:</b>		<b>Last Well Visit:</b> <b>Portal Access:</b> 03/18/2020	
----------------------------------------------------------------------------------	----------------------------------------------------	------------------------------------------------------------------------------------	-------------------------------------------------------------	-------------------------------------------------------------------------------------

<u>DIAGNOSES (2)</u>	<u>ALERT</u>	<u>MESSAGE</u>	<u>MOST RECENT DATE</u>	<u>MOST RECENT RESULT</u>
ASM      COVID-19	HIV	Missing		
<u>RISK FACTORS (1)</u>	Drug Screening	Missing		
BMI	Sub Use Scr	Missing		
<u>SDOH (2)</u>				

## New Alert


# Dashboards





PERIOD: TY August 2020 | CENTERS: All Centers | RENDERING PROVIDER: All Rendering Provid...

+ Add Filter ⌵ 🔄 Update



### Buprenorphine Tx

**3,574**  
Pts w/ a Buprenorphine Order

#### Pts on Buprenorphine by Race



RACE	NUM
American Indian/Alaska Native	50
Asian	9
Black/African American	277
Ignore	3
More than One Race	53
Native Hawaiian	5
Pacific Islander	3
Unreported/Refused to Report Race	215
White	2,959

#### Pts on Buprenorphine by Ethnicity

ETHNICITY	NUMERATOR	% TOTAL
Hispanic/Latino	183	5%
Non-Hispanic/Latino	2,985	84%
Unmapped	2	0%
Unreported/Refused to Report Ethnicity	404	11%
<b>Totals</b>	<b>3,574</b>	


#### Pts on Buprenorphine by Gender

SEX AT BIRTH	NUMERATOR	% TOTAL
F	1,750	49%
M	1,824	51%
<b>Totals</b>	<b>3,574</b>	



PERIOD: TY August 2020 | CENTERS: All Centers | RENDERING PROVIDER: All Rendering Provid...

+ Add Filter ⌵ 🔄 Update



### Naltrexone Tx

**737**  
Pts w/ a Naltrexone-Injectable Order

#### Pts on Naltrexone by Race



RACE	NUM
American Indian/Alaska Native	8
Asian	1
Black/African American	45
Ignore	2
More than One Race	11
Native Hawaiian	1
Pacific Islander	0
Unreported/Refused to Report Race	43
White	626

#### Pts on Naltrexone by Ethnicity

ETHNICITY	NUMERATOR	% TOTAL
Hispanic/Latino	28	4%
Non-Hispanic/Latino	611	83%
Unmapped	0	0%
Unreported/Refused to Report Ethnicity	98	13%
<b>Totals</b>	<b>737</b>	

#### Pts on Naltrexone by Gender

SEX AT BIRTH	NUMERATOR	% TOTAL
F	342	46%
M	395	54%
<b>Totals</b>	<b>737</b>	



# Cohorts

Opioid Use Disorder Treatment (OUD) MEASURE

PERIOD: August 2020 | CENTERS: All Centers | RENDERING PROVIDER: All Rendering Provid... | USUAL PROVIDER: All Usual Provider

MEASURE ANALYZER

DETAIL LIST

Cohort Administration

Search Cohorts...

NAME ▾	# OF PATIENTS	CREATED DATE
eMAT - Jan - Mar 2019	124	03/26/2019
IjMAT Patients 2019	81	02/03/2020
IjSUD	56	09/12/2019
IjSUD patients	759	01/23/2020

MRN	NUMERATOR
156530	N
134608	N
26620	N
49288	N
0000008109	N
0000005450	N
0000003364	N
180813	N
12160	N
21057	N
23407	N
17758	N
42997	N

Copy Ctrl+C

EXPORT EXCEL

CREATE COHORT



# Utilizing the Data in Azara

**Controlled Substance** REPORT

PERIOD: February 2020 | CENTERS: All Centers | RENDERING PROVIDER: All Rendering Provid... | USUAL PROVIDER: All Usual Provider

**REPORT** CARE GAPS

GROUPING: No Grouping

MEASURE	RESULT	NUMERATOR	DENOMINATOR
Continuity of Pharmacotherapy for Opioid Use Disorder (NQF 3175)	70.3%	189	
Naloxone Prescription with Chronic Opioid Therapy	8.4%	111	
Naloxone Prescription with Opioid Use Disorder	12.3%	303	
Drug Use Screening	34.0%	20,260	
Unhealthy Alcohol Use: Screening (NQF 2152 Modified)	34.4%	15,755	
Unhealthy Alcohol Use: Screening & Brief Counseling (NQF 2152)	33.2%	19,830	59,640

**Filter Menu:**

- ALL
- 4Cut Provider
- ACE Score
- Baseline Period
- Cohort**
- Concency
- Financial Class
- Gender Identity
- Housing Situation
- Language
- Migrant Worker Status
- Patient Diagnoses
- Patient Risk

**+ Add Filter**

**Controlled Substance** REPORT

PERIOD: February 2020 | CENTERS: All Centers | RENDERING PROVIDER: All Rendering Provid... | USUAL PROVIDER: All Usual Provider | **COHORT: All Cohort**

**REPORT**

GROUPING: No Grouping

**Search:** sud

**Clear Filters**

- SUD
- SUD patients

MEASURE	RESULT	NUMERATOR
Continuity of Pharmacotherapy for Opioid Use Disorder (NQF 3175)	70.3%	
Naloxone Prescription with Chronic Opioid Therapy	8.4%	
Naloxone Prescription with Opioid Use Disorder	12.3%	
Drug Use Screening	34.0%	

# Transitions of Care



The screenshot shows a mobile application interface with a sidebar on the left and a main content area on the right. The sidebar contains several icons and labels: a green circle with 'a', a calendar icon labeled 'PVP', a person icon labeled 'CMP', a clipboard icon labeled 'Reports' (highlighted with a red box), a dashboard icon labeled 'Dashboards', a bar chart icon labeled 'Measures', a list icon labeled 'Registries', and a gear icon labeled 'Admin'. The main content area is titled 'Reports' and features a search bar. Below the search bar, there are several menu items: 'MY PINS' (with a dropdown arrow), 'MPCA 2018 UDS with Targets' (with an information icon), 'LIBRARY' (with a dropdown arrow), 'UDS' (with an up arrow), 'Care Management Passport' (with an up arrow), 'Clinical Operations' (with an up arrow), 'Controlled Substance' (with an up arrow), 'Dental CQM' (with an up arrow), 'HEDIS' (with an up arrow), 'Meaningful Use' (with an up arrow), 'MICare' (with an up arrow), 'MillionHearts' (with an up arrow), 'OB' (with an up arrow), 'Payer Integration' (with an up arrow), 'PCMH' (with an up arrow), 'Referrals' (with an up arrow), 'Transition of Care' (with a dropdown arrow and highlighted by a red box), 'Transition of Care - ED' (with an information icon and highlighted by a red box), 'Transition of Care - IP' (with an information icon and highlighted by a red box), and 'Custom Scorecards' (with an up arrow).

# TOC - Search by Substance

		DIAGNOSIS		NEXT APPOINTMENT	
VISITS LAST 6 MONTHS	DISCHARGE STATUS CODE	CODE	DESCRIPTION		
5	05	T50.901A	Poisoning by unspecified drugs, medicaments and biological substances, a	substance	
2	05	F19.10	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED	<input type="checkbox"/> (Select All)	
4	01	F19.10	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED	<input checked="" type="checkbox"/> Adverse effect of unspecified drugs, i	
al	2	F19.950	OTHER PSYCHOACTIVE SUBSTANCE USE, UNSPECIFIED WITH PSYCHOACTI	<input checked="" type="checkbox"/> Encounter for observation for suspec	
-W...	5	F19.10	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED	<input checked="" type="checkbox"/> OTHER PSYCHOACTIVE SUBSTANCE	
	2	F19.10	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED	<input checked="" type="checkbox"/> OTHER PSYCHOACTIVE SUBSTANCE	
	1	T50.901A	Poisoning by unspecified drugs, medicaments and biological substances, ac	<input checked="" type="checkbox"/> OTHER PSYCHOACTIVE SUBSTANCE	
	3	F29	UNSPECIFIED PSYCHOSIS NOT DUE TO A SUBSTANCE OR KNOWN PHYSIOL	<input checked="" type="checkbox"/> OTHER PSYCHOACTIVE SUBSTANCE	
	6	F19.11	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, IN REMISSION	<input checked="" type="checkbox"/> OTHER PSYCHOACTIVE SUBSTANCE	
	1	T50.901A	Poisoning by unspecified drugs, medicaments and biological substances, ac		Jodi
	3	F19.10	OTHER PSYCHOACTIVE SUBSTANCE ABUSE, UNCOMPLICATED		
	3	F29	UNSPECIFIED PSYCHOSIS NOT DUE TO A SUBSTANCE OR KNOWN PHYSIOLOG...		

# TOC - Search by Cohort

RENDERING PROVIDER: All Rendering Provid... + Add Filter ⌵ ↻ Update

COHORT: 2 selected ⓧ

Search: sud 🔍

Clear Filters

- SUD
- SUD patients

DISCHARGE	DIAGNOSIS	NEXT APPOINTMENT	RISK	RISKSCORE
0 11:31 am 8/26/20 2:41 pm	R19.7 Diarrhea, unspecified		Moderate	13
0 6:01 pm 8/24/20 9:43 pm	Z76.89 Persons encountering health services in other speci...		Low	5
0 3:35 pm 8/29/20 7:40 pm	R10.9 Unspecified abdominal pain		Low	3
0 1:40 am 8/27/20 2:55 am			Low	6
0 12:56 am 8/29/20 1:47 am			Low	6
0 8:14 pm 8/26/20 10:22 pm	Z04.89 ENCOUNTER FOR EXAMINATION AND OBSERVATIO...	9/3/2020	Moderate	12
0 12:59 pm 8/30/20 3:25 pm		9/3/2020	High	15



# Patient Risk Stratification

Patient Risk Stratification
FILTER
+
Update

PERIOD: TY February 2020
CENTERS: All Centers
RENDERING PROVIDER: All Rendering Provid...

### Risk Criteria Weighting

DIAGNOSES	PATIENT COUNT	PREVALENCE	% HIGH RISK	POINTS
Diabetes	50,987	12%	21%	2
Hypertension	117,513	27%	13%	2
Hyperlipidemia	87,277	20%	12%	1
ASCVD	17,632	4%	30%	1
CHF	6,556	2%	42%	3
CAD	12,534	3%	34%	2
Ischemic Stroke	2,820	1%	29%	1
Hemorrhagic Stroke	331	0%	20%	2
IVD				
Afib				
Persistent Asthma				
COPD				
Chronic NonMalignant Pain				
Cirrhosis				
CKD Stages 3&4				
CKD Stage 5				
ESRD				
HIV				
Chronic Hepatitis C				
Cerebral Palsy				
Physiological Developmental				

### Risk Category Distribution

Legend: Low (blue), Moderate (dark blue), High (orange)

### High Risk Patients

**23,798**  
Count of Pts with Primary Care Encounter in period

### Total Patients

**436,675**  
Count of Pts with Primary Care Encounter in period

### Risk Score Thresholds

Pediatric (0-21)			
CATEGORY	# PATIENTS	PREVALENCE	THRESHOLD
High	7,318	5%	8.00
Moderate	17,930	13%	5.00
Low	113,230	82%	0
Adult (22-64)			
CATEGORY	# PATIENTS	PREVALENCE	THRESHOLD
High	14,092	6%	14.00
Moderate	40,606	16%	9.00
Low	197,895	78%	0
Geriatric (65-149)			
CATEGORY	# PATIENTS	PREVALENCE	THRESHOLD
High	2,388	5%	16.00
Moderate	7,477	17%	11.00
Low	35,045	78%	0

### Risk Score Distribution

BEHAVIORAL HEALTH	PATIENT COUNT	PREVALENCE	% HIGH RISK	POINTS
Severe Mental Illness	84,298	19%	18%	1
Schizophrenia	8,538	2%	21%	2
Bipolar Disorder	20,244	5%	22%	2
Anxiety	85,436	20%	14%	1
Depression	89,022	20%	16%	1
Dementia & Mental Degenerations	1,413	0%	21%	2
Autism Spectrum Disorders	2,924	1%	20%	1
ADHD	21,105	5%		
Severe Emotional Disturbance (SED)	33,428	8%		
Tobacco User	101,004	23%		
SAD/SUD	41,458	9%		
Illicit Drug Use Disorders	16,775	4%		
Drug Overdose	183	0%		

### MEDICATIONS

MEDICATIONS	PATIENT COUNT	PREVALENCE	% HIGH RISK	POINTS
Anticoagulant Medications	7,381	2%	27%	2
High Risk Medications for the Elderly (->1)	11,195	3%	10%	1
Chronic Opioid Therapy (Z79.891)	4,045	1%	22%	1

### UTILIZATION

UTILIZATION	PATIENT COUNT	PREVALENCE	% HIGH RISK	POINTS
1-2 I/P Episodes in last 6 mos	19,689	5%	13%	0
3 I/P Episodes in last 6 mos	1,068	0%	28%	1
>3 I/P Episodes in last 6 mos	889	0%	43%	2
1-2 E/D Episodes in last 6-mos	67,687	16%	8%	0
3 E/D Episodes in last 6-mos	6,271	1%	15%	1
>3 E/D Episode in last 6-mos	6,059	1%	24%	2

### Rising Risk Patients

**3,889**  
Pts w/ New High Risk Level

# Risk & Filters

**Patient Risk Stratification** DASHBOARD

FILTER ^

+ Add Filter v Update

PERIOD: TY August 2020

CENTERS: All Centers

RENDERING PROVIDER: All Rendering Provid...

PATIENT DIAGNOSES: Alcohol/Substance D... x

COHORT: MAT Patients 2019 x

CARE MANAGER: All Care Manager x

**Risk Criteria Weighting**

DIAGNOSES	PATIENT COUNT	PREVALENCE	% HIGH RISK	POINTS
Diabetes	4	6%	75%	2
Hypertension	11	17%	64%	2
Hyperlipidemia	5	8%	40%	1
ASCVD	1	2%	100%	1
CHF	0	0%	0%	3
CAD	0	0%	0%	2
Ischemic Stroke	0	0%	0%	1
Hemorrhagic Stroke	1	2%	100%	2
IVD	0	0%	0%	1
Afib	1	2%	100%	2
Persistent Asthma	5	8%	40%	2
COPD	4	6%	75%	2
Chronic NonMalignant Pain	22	34%	36%	1
Cirrhosis	0	0%	0%	2
CKD Stages 3&4	1	2%	100%	1
CKD Stage 5	0	0%	0%	2
ESRD	0	0%	0%	1
HIV	0	0%	0%	1
Chronic Hepatitis C	11	17%	45%	3
Cerebral Palsy	0	0%	0%	2

**Risk Category Distribution**

■ Low ■ Moderate ■ High

**High Risk Patients**

13

Count of Pts with Primary Care Encounter in period

---

**Total Patients**

65

Count of Pts with Primary Care Encounter in period

**Risk Score Distribution**

**Risk Score Thresholds**

Pediatric (0-21)			
CATEGORY	# PATIENTS	PREVALENCE	THRESHOLD
High		0%	8.00
Moderate		0%	5.00
Low		0%	0
Adult (22-64)			
CATEGORY	# PATIENTS	PREVALENCE	THRESHOLD
High	13	20%	14.00
Moderate	25	38%	9.00
Low	27	42%	0
Geriatric (65-149)			
CATEGORY	# PATIENTS	PREVALENCE	THRESHOLD
High		0%	16.00
Moderate		0%	11.00
Low		0%	0


**Rising Risk Patients**

2


Pts w/ New High Risk Level

# Compliance as Part of Quality

Overall Risk Distribution



Sub-Population (SUD Cohort)  
Risk Distribution



# Compliance as Part of Quality

Do you look beyond clinical outcomes to measure quality?

Process measures= standards of care

MEDICATION NAME	PRESCRIPTION DATE	PDMP
Suboxone	1/2/2020	No Same Day PDMP
Suboxone	1/2/2020	No Same Day PDMP
Suboxone	1/2/2020	No Same Day PDMP
Suboxone	1/2/2020	No Same Day PDMP

<a href="#">Controlled Substance Agreement with Chronic Opioid Therapy</a>	38.4%
<a href="#">Controlled Substance Agreement w/Chronic Non Malignant Pain</a>	18.3%

# Prescriber Data

Can monitor # patients on MAT by provider – do they have adequate resources for the number they are treating?

The screenshot shows a report interface with the following elements:

- Report Title:** Medication-Assisted Therapy prescribed for OUD by Provider Report
- Filters:** PERIOD (2020), CENTERS (All Centers), RENDERING PROVIDER (All Rendering Provid...)
- Search:** Search Patients ...
- Table:** A table with two columns: 'PRESCRIBING PROVIDER' and 'NUMBER OF PATIENTS'. The table is sorted by the number of patients in descending order.

PRESCRIBING PROVIDER	NUMBER OF PATIENTS ↓
Pr...	361
U...	292
G...	209
SC...	191
Pe...	176
Le...	171
M...	149
IV...	143
SE...	119
CI...	118
Cr...	101
SI... n...	94
Pr...	91

# Care Management & MAT

Manage case loads and patients



Medication-Assisted Therapy prescribed for OUD by Provider Detail List REPORT FILTER + Update

PERIOD: August 2020 | CENTERS: All Centers | RENDERING PROVIDER: All Rendering Provid... | **CARE MANAGER: All Care Manager** + Add Filter Update

Search Patients ...

PATIENT NAME	MRN	SEX AT BIRTH	LANGUAGE	ETHNICITY	RACE	SUAL PROVIDER	DATE OF BIRTH	PRESCRIBING PROVIDER	MEDICATION NAME	PRESCRIPTION DATE	PDMP
		F	English	Non-Hispanic/Latino	Black/African American				buprenorphine HCl	8/12/2020	No Same Day
		F	English	Non-Hispanic/Latino	Black/African American				buprenorphine HCl	8/12/2020	No Same Day
		F	English	Non-Hispanic/Latino	Unreported/Refused to Report Race				buprenorphine HCl 8 mg su...	8/11/2020	No Same Day
		F	English	Non-Hispanic/Latino	White				buprenorphine 8 mg-nalox...	8/12/2020	No Same Day
		M	Unreported/Refused to Report Language	Unreported/Refused to Report Ethnicity	Unreported/Refused to Report Race				buprenorphine HCl 8 mg su...	8/12/2020	No Same Day
		F	English	Non-Hispanic/Latino	White				buprenorphine HCl	8/12/2020	No Same Day
		F	English	Non-Hispanic/Latino	White				buprenorphine-naloxone	8/12/2020	No Same Day
		F	English	Non-Hispanic/Latino	White				buprenorphine-naloxone	8/12/2020	No Same Day
		F	English	Non-Hispanic/Latino	White				buprenorphine HCl	8/13/2020	No Same Day
		F	English	Non-Hispanic/Latino	White				Vivitrol	8/14/2020	No Same Day
		M	English	Unreported/Refused to Report Ethnicity	Black/African American				SUBOXONE 8-2 MG SUBLIN...	8/13/2020	No Same Day
		M	English	Hispanic/Latino	Unreported/Refused to Report Race				Naltrexone HCl	8/13/2020	No Same Day
		M	English	Non-Hispanic/Latino	White				Zubsolv 8.6 mg-2.1 mg subli...	8/12/2020	No Same Day
		F	English	Non-Hispanic/Latino	White				naltrexone 50 mg tablet	8/12/2020	No Same Day
		M	English	Non-Hispanic/Latino	White				Vivitrol 380 mg intramuscul...	8/13/2020	No Same Day

# Initiation of Pharmacotherapy over the last 12 months:




# Monitor Initiation vs Engagement!

 **Initiation of AOD Treatment 13+ Years Old (NQF 0004)**

 **Engagement of AOD Treatment 13+ Years Old (NQF 0004)**

 **Continuity of Pharmacotherapy for Opioid Use Disorder (NQF 3175)**

 **Initiation of Pharmacotherapy Upon New Episode of Opioid Dependence (13-17 Years)**

 **Initiation of Pharmacotherapy Upon New Episode of Opioid Dependence (18+ Years)**

 **Initiation of Pharmacotherapy Upon New Episode of Opioid Dependence (18+ Years)**

 Endorser: QARR

 Steward: QARR

 Patients ages 18+ who initiate pharmacotherapy with at least 1 prescription for opioid treatment medication within 30 days following a d

 **Numerator:**

 Initiation of pharmacotherapy treatment within 30 days of the OUD diagnosis.








-  • Buprenorphine or Naltrexone Injectable/Oral with a start date within 30 days of the OUD diagnosis.

 **Denominator:**

 Patients ages 18+ with a new diagnosis of opioid abuse or dependence in the measurement period.





-  • Age 18 as of the end of the measurement period
-  • Qualifying encounter (Medical or Behavioral Health) - See technical specifications
-  • Earliest diagnosis of OUD in the measurement period AND no OUD diagnosis 60 days prior to that diagnosis





### OU D Tx - Type

MEASURE	RESULT	NUM	DENOM	EXCL
Buprenorphine Prescription	39%	4,007	10,404	0
Naltrexone-Injectable Prescription	8%	839	10,404	0
Naloxone Prescription w/OUD	13%	672	5,300	0
Naloxone Prescription w/COT	4%	270	7,507	0



# Managing Risk

## Urine Drug Screen – The other UDS

Office Based Opioid Treatment <sup>1</sup>  
REGISTRY

DATE RANGE: 08/24/2020-08/31/2020  
CENTERS: All Centers  
RENDERING PROVIDER: All Rendering Provid...

REGISTRY VALUE SETS

Search Patients ...

DEMOGRAPHICS >			DRUGS OF ABUSE			MAT DRUG TEST			OVERDOSE		NARCAN	
CENTER NAME	NAME	MRN	DATE	TEST AND RESULT	POS TEST ▾	DATE	NAME AND RESULT	POSITIVE AND DATE ▾ ↓	DATE	DX CODE	DATE	DETAIL
			8/27/2020	Drug Screen - Negative	Cocaine - 08/13/2020, Benzodiazepines - 07/16/2020, THC - 11/27/2018, Opiates - 05/04/2017	8/13/2020	Naloxone Scrn - 372	Norbuprenorphine - 06/01/201...			2/3/2019	Narcan 4 ...
			8/27/2020	Drug Screen - Positive	THC - 04/22/2019, Barbiturates - 08/30/2018	7/30/2020	Buprenorphine Urine - 11	Buprenorphine - 11/04/2019				
			9/18/2019	Amphetamines - NEGATIVE	Cocaine - 09/18/2019, Ethanol - 09/18/2019, Benzodiazepines - 09/18/2019, THC - 03/14/201...	9/18/2019	Buprenorphine Urine - 42	Buprenorphine - 10/17/2017, ...			4/18/2018	Narcan 4 ...
			8/27/2020	Amphetamines - Negative	Barbiturates - 08/27/2020, Benzodiazepines - 08/27/2020, THC - 08/27/2020	8/27/2020	Buprenorphine Urine - 15	Buprenorphine - 08/27/2020	3/4/2020	T40.2X5A		
			8/21/2020	Drug Screen - negative	Opiates - 08/20/2020, Benzodiazepines - 07/21/2020	8/20/2020	Buprenorphine Urine - 63	Buprenorphine - 08/20/2020				
			8/19/2020	Amphetamines - Negative	Cocaine - 08/19/2020, Amphetamines - 08/14/2020, THC - 08/14/2020	8/19/2020	Buprenorphine Urine - Positive	Buprenorphine - 08/19/2020	2/19/2020	T40.2X5A	8/19/2020	Narcan
			8/18/2020	Opiates - negative	Amphetamines - 01/28/2020	8/18/2020	Buprenorphine Urine - positive	Buprenorphine - 08/18/2020				
			8/13/2020	Benzodiazepines - NEGATIVE	Cocaine - 08/13/2020, THC - 08/13/2020	8/13/2020	Buprenorphine Urine - 742	Buprenorphine - 08/13/2020				
			7/29/2020	Cocaine Scrn - Negative	Barbiturates - 07/29/2020, THC - 01/09/2020, Benzodiazepines - 01/09/2020	7/29/2020	Buprenorphine Urine - Positive	Buprenorphine - 07/29/2020	9/4/2019	T40.2X5A	8/26/2020	Narcan
			7/29/2020	Phencyclidine - NEGATIVE	THC - 03/11/2020, Benzodiazepines - 03/11/2020, Opiates - 09/03/2019	7/29/2020	Buprenorphine Urine - positive	Buprenorphine - 07/29/2020				
			7/29/2020	Barbiturates - NEGATIVE	Benzodiazepines - 02/12/2020, Amphetamines - 06/17/2019	7/29/2020	Buprenorphine Urine - 37	Buprenorphine - 07/29/2020				
			7/29/2020	Amphetamines - NEGATIVE	Opiates - 07/29/2020, THC - 07/29/2020, Benzodiazepines - 07/29/2020, Ethanol - 09/04/2019	7/29/2020	Buprenorphine Urine - 303	Buprenorphine - 07/29/2020				
			7/8/2020	Amphetamines - Negative	Amphetamines - 01/08/2020, Opiates - 01/08/2020	7/8/2020	Buprenorphine Urine - Positive	Buprenorphine - 07/08/2020			8/3/2020	Narcan
			7/6/2020	Amphetamines - Negative	THC - 03/16/2020	7/6/2020	Buprenorphine Urine - Positive	Buprenorphine - 07/06/2020			8/3/2020	Narcan
			7/1/2020	Amphetamines - Negative	THC - 01/15/2020, Amphetamines - 12/18/2019, Cocaine - 11/06/2019	7/1/2020	Buprenorphine Urine - Positive	Buprenorphine - 07/01/2020				

# Prevention



## Opioid Medication - Potential Misuse i

REGISTRY

OPIOID MED				CNMP DX			BENZODIAZEPINE			CLONIDINE			GABAPENTIN		
SUBSTANCE AGREEMENT	START DATE	STOP DATE	DETAIL	ASSESSMENT DATE	CODE	DETAIL ▾	START DATE	TOP DATE	NAME ▾	START DATE	STOP DATE	NAME ↓	START DATE	TOP DATE	NAME ▾
	8/12/2020		Percocet	8/12/2020	G89.4	CHRONIC PAIN SYNDRO...	3/18/2020		Valium	1/20/2020	2/20/2020	Clonidine HCl	10/18/2018		Gabapentin
2019	8/12/2020		Norco	7/6/2020	G89.29	OTHER CHRONIC PAIN	8/25/2020		Klonopin	11/5/2018	5/4/2020	Clonidine HCl	11/2/2018	5/4/2020	Gabapentin
1/2018	8/13/2020		Hydrocodone-Acetaminophen	8/16/2017	G89.29	OTHER CHRONIC PAIN	7/24/2020		Klonopin	8/27/2018	7/24/2020	Clonidine HCl	8/11/2020		Gabapentin
	9/25/2017		Norco	8/26/2020	G89.4	CHRONIC PAIN SYNDRO...	9/25/2017		Xanax	9/25/2017		Clonidine HCl	8/26/2020		Gabapentin
1/2018	5/8/2019		Morphine Sulfate	1/28/2019	G89.4	CHRONIC PAIN SYNDRO...	2/22/2019		Halcion	7/30/2018		Clonidine HCl	8/3/2018		Gabapentin
2019	8/26/2020		Oxycodone-Acetaminophen	7/22/2020	G89.29	OTHER CHRONIC PAIN	2/4/2020	8/26/2020	Valium	2/4/2020	8/26/2020	Clonidine HCl	11/1/2019		Gabapentin
	7/31/2020		Oxycodone HCl												
1/2019	4/10/2019		Norco												
	8/6/2020		MS Contin												

DRUGS OF ABUSE				ALCOHOL DISORDER DX			AUD MED		
DATE	TEST AND RESULT	POS TEST	DATE	ODE	DETAIL ▾	START DATE	STOP DATE	NAME ↓	
1/11/2019	Amphetamines - NEGATIVE	Opiates - 01/11/2019	7/13/...	F10...	Alcohol dependence, in re...	6/10/2019		Trokendi XR	
5/27/2020	Opiates - Negative		7/12/...	F10...	ALCOHOL DEPENDENCE, ...	1/31/2019	1/30/2020	topiramate	
8/14/2020	Ethanol - 24	THC - 05/01/2019, Ethanol - 08/13/2018	10/9/...	F10...	ALCOHOL DEPENDENCE, ...	10/22/2018		Topamax	

# Data Hygiene

- To use data you need to have good data
- Filter by Provider Type - do you have dentists prescribing MAT?

**Medication-Assisted Therapy prescribed for OUD by Provider Report**

PERIOD: 2020  
CENTERS: All Centers  
RENDERING PROVIDER: All Rendering Provid...  
USUAL PROVIDER: All Usual Provider  
RENDERING PROVIDER TYPE: Doctor of Dental Me...

Search Patients ...

PRESCRIBING PROVIDER	NUMBER OF PATIENTS
[Redacted]	1
[Redacted]	1
[Redacted]	1
[Redacted]	1
[Redacted]	9
[Redacted]	5

**Medication-Assisted Therapy prescribed for OUD by Provider Report**

Created By: Azara  
Created On: 11/7/2019 12:49:38 PM  
Modified By: Azara  
Modified On: 8/5/2020 5:59:37 PM

List of unique patients prescribed Medication-Assisted Therapy for Opioid Use Disorder by prescribing provider.

Do we document this element in our **EHR**? → No

Do we need a **new structured data field**? → No

Do we need a **new process** or **more training**?

Do we document this element in our **EHR**? → Yes

Do we need a **new process** or **more training**?

Is there more to do with our Controlled Substance Module?



**Questions?**